Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
ODT-CRS
1 other identifier
observational
1,200
1 country
1
Brief Summary
To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
May 26, 2022
CompletedFirst Posted
Study publicly available on registry
May 31, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
June 2, 2022
April 1, 2022
10.9 years
May 26, 2022
May 30, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Hospitalization due to worsening of renal or cardiac function
eGFR continuously decreased by more than 25% within one year; NYHA cardiac function class III or above requires intravenous pharmacological agents; deterioration of cardiac or kidney function requiring dialysis
1 year
All-cause deaths
Deaths due to disease progression
1 year
Secondary Outcomes (2)
End-stage renal disease requires maintenance dialysis
1 year
Acute kidney injury
1 year
Study Arms (2)
acute kidney injury
Acute kidney injury caused by heart disease or cardiac dysfunction due to acute renal damage
chornic kidney disease
Chornic kidney injury caused by heart disease or cardiac dysfunction due to chronic kidney disease
Interventions
Eligibility Criteria
Patients from a tertiary hospital
You may qualify if:
- Patients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney.
You may not qualify if:
- Pregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unknown Facility
Nanjing, China
Biospecimen
serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2022
First Posted
May 31, 2022
Study Start
January 1, 2016
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2027
Last Updated
June 2, 2022
Record last verified: 2022-04